Top

Published in:

Open Access 01-12-2011 | Case report

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Authors: Alexander Shimabukuro-Vornhagen, Achim Rothe, Lucia Nogova, Matthias Kochanek, Christoph Scheid, Michael von Bergwelt-Baildon

Published in: Journal of Medical Case Reports | Issue 1/2011

Abstract

Introduction

In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL ⁺ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL ⁺ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders.

Case presentation

We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib.

Conclusion

This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL ⁺ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia.

Available only for authorised users

Inokuchi K, Nomura T: The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia. Leuk Lymphoma. 1993, 10: 9-15.CrossRefPubMed

Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ: BCR-ABL expression in different subpopulations of functionally characterized Ph⁺ CD34⁺ cells from patients with chronic myeloid leukemia. Blood. 1996, 88: 1796-1804.PubMed

Thiele J, Schmitz B, Fuchs R, Kvasnicka HM, Lorenzen J, Fischer R: Detection of the bcr/abl gene in bone marrow macrophages in CML and alterations during interferon therapy: a fluorescence in situ hybridization study on trephine biopsies. J Pathol. 1998, 186: 331-335. 10.1002/(SICI)1096-9896(199811)186:3<331::AID-PATH178>3.0.CO;2-7.CrossRefPubMed

Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, Rovida E, Morra E: The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000, 36: 1395-1401. 10.1016/S0959-8049(00)00128-3.CrossRefPubMed

Savage DG, Szydlo RM, Goldman JM: Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997, 96: 111-116. 10.1046/j.1365-2141.1997.d01-1982.x.CrossRefPubMed

Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984, 64: 1-12.PubMed

Thiele J, Schmitz B, Gross H, Kvasnicka HM, Niederle N, Leder LD, Fischer R: Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-α therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation. Histopathology. 1997, 31: 215-221. 10.1046/j.1365-2559.1997.2480853.x.CrossRefPubMed

Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, Linkesch W: Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002, 99: 381-383. 10.1182/blood.V99.1.381.CrossRefPubMed

Thiele J, Kvasnicka HM, Varus E, Ollig E, Schmitt-Graeff A, Staib P, Griesshammer M: Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy: a fluorescence in-situ hybridization study. Leuk Lymphoma. 2004, 45: 1627-1631. 10.1080/10428190410001683732.CrossRefPubMed

10.

Nolte M, Werner M, Ewig M, von Wasielewski R, Link H, Diedrich H, Georgii A: Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies. Virchows Arch. 1996, 427: 561-565.CrossRefPubMed

11.

Era T: Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells. Int J Hematol. 2002, 76: 35-43. 10.1007/BF02982716.CrossRefPubMed

12.

Buet D, Raslova H, Geay JF, Jarrier P, Lazar V, Turhan A, Morlé F, Vainchenker W, Louache F: p210^BCR-ABL reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription: megakaryocytic to erythroid reprogramming by p210^BCR-ABL. Leukemia. 2007, 21: 917-925.PubMed

Title: Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
Authors: Alexander Shimabukuro-Vornhagen
Achim Rothe
Lucia Nogova
Matthias Kochanek
Christoph Scheid
Michael von Bergwelt-Baildon
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2011
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/1752-1947-5-215

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Abstract

Introduction

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Osteoid osteoma of the femoral head treated by radiofrequency ablation: a case report

Respiratory failure presenting in H1N1 influenza with Legionnaires disease: two case reports

One-stage laparoscopic-assisted resection of gastrojejunocolic fistula after gastrojejunostomy for duodenal ulcer: a case report

Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

Primary extra-cranial meningioma in the right submandibular region of an 18-year-old woman: a case report

Metastatic breast carcinoma in the mandible presenting as a periodontal abscess: a case report